当前位置: 首页 > 期刊 > 《中国当代医药》 > 2012年第19期 > 正文
编号:12277088
瑞舒伐他汀和阿伐他汀对急性冠状动脉综合征患者血脂、超敏C-反应蛋白和冠状动脉支架植入术后再狭窄的影响(1)
http://www.100md.com 2012年7月5日 马文学 江志羔 古玉燕 毕健成 徐志奇
第1页

    参见附件。

     [摘要] 目的 观察瑞舒伐他汀和阿托伐他汀对急性冠状动脉综合征患者血脂、炎症因子和冠状动脉支架植入术后再狭窄的影响。 方法 111例急性冠状动脉综合征支架植入患者,随机分为瑞舒伐他汀组(瑞舒伐他汀20 mg+常规用药)和阿托伐他汀组(阿托伐他汀40 mg+常规用药),术前和术后6个月分别检查总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)和超敏C反应蛋白(hs-CRP),复查冠状动脉造影,测量支架内再狭窄率,记录心绞痛发生率,比较两组之间的差别。 结果 瑞舒伐他汀组TC、TG、LDL-C、Hs-CRP和心绞痛发生率均较阿托伐他汀组低(P < 0.05),HDL-C高于阿托伐他汀组,支架内再狭窄率两组差异无统计学意义(P > 0.05)。 结论 瑞舒伐他汀较阿托伐他汀有更强的调脂和抗炎作用,能减少心绞痛的发生率。

    [关键词] 瑞舒伐他汀;阿托伐他汀;急性冠状动脉综合征;C-反应蛋白;再狭窄

    [中图分类号] R541.4 [文献标识码] A [文章编号] 1674-4721(2012)07(a)-0030-03

    Effect of Rosuvastatin and Atorvastatin on lipid, hs-CRP and restenosis after coronary stenting of patients with acute coronary syndrome

    MA Wenxue JIANG Zhigao GU Yuyan BI Jiancheng XU Zhiqi ZENG Jianxin

    Department of Cardiology, the People's Hospital of Huadu District of Guangzhou City in Guangdong Province, Guangzhou 510800, China

    [Abstract] Objective To observe the effect of Rosuvastatin and Atorvastatin on blood lipid, CRP and restenosis after coronary stenting of patients with acute coronary syndrome. Methods One hundred and eleven patients with acute coronary syndrome after PCI were randomly divided into Rosuvastatin group (Rosuvastatin 20 mg+routine treatment) and Atorvastatin group (Atorvastatin 40 mg+routine treatment). Before and after operation for 6 months, TC, TG, LDL-C, HDL-C and hs-CRP were detected, the coronarography was rechecked, the rate of restenosis was measured, the incidence of angina was recorded, and the differences of the two groups were compared. Results TC, TG, LDL-C, hs-CRP and the incidence of angina in Rosuvastatin group were all lower than those in Atorvastatin group (P < 0.05), while HDL-C was higher than that in Atorvastatin group. But there was no statistically significant difference of the incidence of restenosis between the two groups (P > 0.05). Conclusion Rosuvastatin has stronger effects in regulating lipid, anti-inflammation and lowering incidence of angina than Atorvastatin.

    [Key words] Rosuvastatin; Atorvastatin; Acute coronary syndrome; Hs-CRP; Restenosis

    急性冠脉综合征(ACS)包括不稳定型心绞痛、非ST段抬高性心肌梗死和ST段抬高性心肌梗死等 ......

您现在查看是摘要介绍页,详见PDF附件(3198kb)